Talk:Vascular endothelial growth factor
| This is the talk page for discussing improvements to the Vascular endothelial growth factor article. This is not a forum for general discussion of the article's subject. |
Article policies
|
| Find sources: Google (books · news · scholar · free images · WP refs) · FENS · JSTOR · TWL |
 | This article is rated C-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: | |||||||||||||||||||||||
| ||||||||||||||||||||||||
Question
editAnyone know what size(s) VEGF A would run at on an SDS-PAGE gel under reducing conditions? 21 kDa reduced, 42 non-reduced
Who first discovered it?
- From Online Mendelian Inheritance in Man (OMIM): 192240: it was first discovered by Ferrara & Henzel in 1989. See PMID 2735925 for the abstract of that study. JFW | T@lk 14:59, 19 September 2005 (UTC)
- Have to correct this. It was first discovered by Senger et al. in 1983 and originally described as EPF (Endothelial Permeability Factor) for its effects on increasing the permeability of vascular endothelium. See PMID 6823562 for an abstract.
Did anyone notice that the picture of VEGF proteins and their receptors has a mistake in it? It has an arrow pointing from VEGF-A to VEGFR-3. I thought VEGF-A only binds to VEGFR-1 and 2. It says so within the article, also. Is the picture wrong or the article? 136.227.165.7 (talk) 08:20, 22 October 2008 (UTC)
Voske (talk) 21:10, 6 July 2009 (UTC) I am quite sure VEGF-A does not bind the VEGFR-3 - there are a lot of articles that you can found showing this.[1]
Classification
editRight now there are two alternative classifications, which is confusing. Is it possible that the "alternative classification" actually is the classification of VEGF-A? It might have been left here, although what was called VEGF historically is now called VEGF-A. Mikael Häggström (talk) 14:00, 30 January 2008 (UTC)
Indeed, you are right - the alternative classification mentioned here is about the different isoforms of VEGF-A (or also referred to as VEGF) - for instance for VEGF-B, also two different isoforms exist: VEGF-B167 and VEGF-B186
This section should be revised.
Embryonic angiogenesis
editI have serious doubts about he fact that VEGF-B might be involved in embryonic angiogenesis - I would strongly recommend to delete this on this page unless strong evidence (references) are provided that wil prove this statement. User:Voske 20:56, 6 July 2009 (UTC)
- If it's not cited, you are welcome to delete, otherwise: http://www.ncbi.nlm.nih.gov/pubmed/21629157 Bloomingdedalus (talk) 23:19, 27 June 2011 (UTC)
- First comment in 13 years! (Sorry for this) Iamamodforjellymario (talk) 07:57, 5 August 2024 (UTC)
Anti-VEGF Therapies and Pediatric Ophthalmology
edit(note: I'm recording the following here as much as a placeholder/reminder for anticipated publication later, as it's not yet suitably verifiable for inclusion in the main article...hope this is ok)
In addition to age-related macular degeneration, anti-VEGF therapies are also being explored as a treatment for corneal neovascularization and ophthalmic post-operative scar formation. Research using rat models by Amano, Rohan et al have demonstrated that the specific inhibition of VEGF bioactivity can significantly suppress corneal vascularization.[2]
In 2009, Li, Van Bergen et al concluded that VEGF was involved in the scarring process based on the observed levels of VEGF in the aqueous humor of glaucoma patients and rabbit models.[3]
(The following is, as yet, unverifiable as its pending future publication) As a result of research like this, anti-VEGF therapies are now being considered for clinical application in pediatric ophthalmology. Some applications have already taken place on eight infants, although this has generated some controversy due to the risk that ocular application in an infant may inhibit desired VEGF bioactivity in the brain. It is recommended that such therapy is applied to children aged eight and over, as cerebral vascular development should have completed by then. K.K. Nischal et al looking into this, results anticipated circa April 2010. (I'll ask Ken for links/references to publications of this work for proper citation and possible inclusion in the main article). Jimjmoore (talk) 12:25, 15 December 2009 (UTC)
References
- ^ Ellis LM, Hicklin DJ (2008). "VEGF-targeted therapy: mechanisms of anti-tumour activity". Nat. Rev. Cancer. 8 (8): 579–91. doi:10.1038/nrc2403. PMID 18596824.
{{cite journal}}: Unknown parameter|month=ignored (help) - ^ Amano, Rohan; et al. (1998). "Requirement for vascular endothelial growth factor in wound and inflammation related corneal neovascularization". Investigative Ophthalmology and Vis. Sci. 39 (1): 18–22. PMID 9430540.
{{cite journal}}: Explicit use of et al. in:|author=(help); Unknown parameter|month=ignored (help) - ^ Li, Van Bergen; et al. (2009). "Inhibition of vascular endothelial growth factor reduces scar formation after glaucoma filtration surgery". Investigative Ophthalmology and Vis. Sci. 50 (11): 5217–25. PMID 19474408.
{{cite journal}}: Explicit use of et al. in:|author=(help); Unknown parameter|month=ignored (help)
Remove large AMD section elsewhere
editThe large section Ranibizumab vs. Bevacizumab for Treating Neovascular Age-related Macular Degeneration unbalances this VEGF article. Most of it could go in an AMD article with just a one line summary here ? Rod57 (talk) 01:27, 31 March 2011 (UTC)